Summary
2.94 -0.02(-0.58%)09/09/2024
Evogene Ltd (EVGN)
Evogene Ltd (EVGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.58 | -11.41 | -31.87 | 333.82 | 222.37 | 283.12 | 73.53 | 9.26 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.94 | |
| Open | 3.00 | |
| High | 3.01 | |
| Low | 2.91 | |
| Volume | 8,837 | |
| Change | -0.02 | |
| Change % | -0.58 | |
| Avg Volume (20 Days) | 31,984 | |
| Volume/Avg Volume (20 Days) Ratio | 0.28 | |
| 52 Week Range | 0.45 - 5.70 | |
| Price vs 52 Week High | -48.37% | |
| Price vs 52 Week Low | 553.96% | |
| Range | -4.84 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 15 | |
| EBIDTA | -24,701,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 2.42 | |
| Book Value | 0.2380 | |
| Earnings Per Share | -0.5200 | |
| EPS Estimate Current Quarter | -0.1400 | |
| EPS Estimate Next Quarter | -0.0500 | |
| EPS Estimate Current Year | -0.4200 | |
| EPS Estimate Next Year | -0.3300 | |
| Diluted EPS (TTM) | -0.5200 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -13.1972 | |
| Return on asset (TTM) | -0.3090 | |
| Return on equity (TTM) | -0.8178 | |
| Revenue TTM | 5,640,000 | |
| Revenue per share TTM | 0.1230 | |
| Quarterly Revenue Growth (YOY) | -0.1240 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 766,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.1204 | |
| Revenue Enterprise Value | 3.3526 | |
| EBITDA Enterprise Value | -0.8129 | |
| Shares | ||
| Shares Outstanding | 50,659,400 | |
| Shares Float | 46,633,151 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.66 | |
| Institutions (%) | 8.99 | |
08/23 08:55 EST - prnewswire.com
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering.
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering.
08/22 17:42 EST - seekingalpha.com
Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript
Evogene Ltd. (NASDAQ:EVGN ) Q2 2024 Earnings Conference Call August 22, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Yoash Zohar - CEO, Casterra Dan Jacob Gelvan - CEO, AgPlenus Ltd Amit Noam - CEO, Lavie BIO Conference Call Participants Operator Welcome to Evogene's Second Quarter Results Conference Call.
Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript
Evogene Ltd. (NASDAQ:EVGN ) Q2 2024 Earnings Conference Call August 22, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Yoash Zohar - CEO, Casterra Dan Jacob Gelvan - CEO, AgPlenus Ltd Amit Noam - CEO, Lavie BIO Conference Call Participants Operator Welcome to Evogene's Second Quarter Results Conference Call.
08/22 11:53 EST - investorplace.com
EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024
Evogene (NASDAQ: EVGN ) just reported results for the second quarter of 2024. Evogene reported earnings per share of -$1.06.
EVGN Stock Earnings: Evogene Misses EPS, Beats Revenue for Q2 2024
Evogene (NASDAQ: EVGN ) just reported results for the second quarter of 2024. Evogene reported earnings per share of -$1.06.
08/22 07:00 EST - prnewswire.com
Evogene Reports Second Quarter 2024 Financial Results
Conference call and webcast: today, August 22 , 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023. Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million.
Evogene Reports Second Quarter 2024 Financial Results
Conference call and webcast: today, August 22 , 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023. Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million.
08/12 07:11 EST - prnewswire.com
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
08/12 07:00 EST - prnewswire.com
Evogene Schedules Second Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024.
Evogene Schedules Second Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel , Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024.
07/31 07:00 EST - prnewswire.com
Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
Castor seeds from Brazil will be ready for shipment during third quarter of 2024. Castor harvest season in Africa started as planned.
Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil
Castor seeds from Brazil will be ready for shipment during third quarter of 2024. Castor harvest season in Africa started as planned.
07/23 08:48 EST - prnewswire.com
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel , July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024.
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued andoutstanding REHOVOT, Israel , July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024.
07/17 08:00 EST - prnewswire.com
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
More than one dozen novel microbes identified for row crops suffering from extreme weather conditions TEL AVIV and REHOVOT, Israel , July 17, 2024 /PRNewswire/ -- ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd.
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
More than one dozen novel microbes identified for row crops suffering from extreme weather conditions TEL AVIV and REHOVOT, Israel , July 17, 2024 /PRNewswire/ -- ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd.
07/02 07:00 EST - prnewswire.com
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Lavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season REHOVOT, Israel , July 2, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.
Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat
Lavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season REHOVOT, Israel , July 2, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.
06/25 07:00 EST - prnewswire.com
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Current castor seed production is expected to support the supply of the new order in 2024, valued at ~ $440K REHOVOT, Israel , June 25, 2024 /PRNewswire/ -- Casterra Ag Ltd ., a subsidiary of Evogene Ltd.
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Current castor seed production is expected to support the supply of the new order in 2024, valued at ~ $440K REHOVOT, Israel , June 25, 2024 /PRNewswire/ -- Casterra Ag Ltd ., a subsidiary of Evogene Ltd.
05/28 16:00 EST - businesswire.com
EverGen Infrastructure Reports Q1 2024 Results
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), today reported financial results as at and for Q1 2024. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS Accounting Standards. Financial and Operational Summary: Three months ended Mar 31, 2024 Mar 31, 2023 $ Change % Change FINANCIAL Revenue 3,227 1,683 1,544 92 Net loss (1,326 ) (996 ).
EverGen Infrastructure Reports Q1 2024 Results
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), today reported financial results as at and for Q1 2024. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS Accounting Standards. Financial and Operational Summary: Three months ended Mar 31, 2024 Mar 31, 2023 $ Change % Change FINANCIAL Revenue 3,227 1,683 1,544 92 Net loss (1,326 ) (996 ).
05/23 11:00 EST - prnewswire.com
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting.
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting.
05/23 07:00 EST - prnewswire.com
Evogene Reports First Quarter 2024 Financial Results
Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.
Evogene Reports First Quarter 2024 Financial Results
Conference call and webcast: today, May 23, 2024, 9:00 am ET Financial and Business Highlights: Q1 2024 revenue: $4.2M vs. $0.6M in Q1 2023; anticipating continued growth in 2024.
05/22 16:05 EST - businesswire.com
EverGen Infrastructure Announces Dates for 2024 First Quarter Financial Results and Conference Call
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), today announced plans to release its 2024 first quarter financial results on May 28, 2024, after market close. EverGen will hold a results and corporate update conference call at 11:00 a.m. eastern time on Wednesday, May 29, 2024, hosted by Chief Executive Officer, Mischa Zajtmann and Chief Financial Officer, Sean Hennessy. Conference Call Details are as follows:.
EverGen Infrastructure Announces Dates for 2024 First Quarter Financial Results and Conference Call
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), today announced plans to release its 2024 first quarter financial results on May 28, 2024, after market close. EverGen will hold a results and corporate update conference call at 11:00 a.m. eastern time on Wednesday, May 29, 2024, hosted by Chief Executive Officer, Mischa Zajtmann and Chief Financial Officer, Sean Hennessy. Conference Call Details are as follows:.
05/21 07:03 EST - prnewswire.com
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
These agreements are expected to support the production of approximately 500 tons of additional seeds, enabling the completion of standing orders by the end of 2024 and positioning Casterra to fulfill future orders. REHOVOT, Israel , May 21, 2024 /PRNewswire/ -- Casterra Ag Ltd.
Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds
These agreements are expected to support the production of approximately 500 tons of additional seeds, enabling the completion of standing orders by the end of 2024 and positioning Casterra to fulfill future orders. REHOVOT, Israel , May 21, 2024 /PRNewswire/ -- Casterra Ag Ltd.
05/09 07:00 EST - prnewswire.com
Evogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel , May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
Evogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel , May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
04/16 07:00 EST - prnewswire.com
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel , April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel , April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
04/11 07:00 EST - prnewswire.com
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
REHOVOT, Israel , April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
REHOVOT, Israel , April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
04/02 07:00 EST - prnewswire.com
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
Finally Foods is financed by the Israeli Innovation Authority (IIA) and The Kitchen Hub, and will be granted a license to utilize Evogene's AI technology REHOVOT, Israel , April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Israeli food giant Strauss Group, have jointly announced the establishment of Finally Foods Ltd.
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
Finally Foods is financed by the Israeli Innovation Authority (IIA) and The Kitchen Hub, and will be granted a license to utilize Evogene's AI technology REHOVOT, Israel , April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Israeli food giant Strauss Group, have jointly announced the establishment of Finally Foods Ltd.